We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis.
- Authors
Gaweł, Władysław B.; Deja, Grażyna; Kamińska, Halla; Tabor, Aleksandra; Skała‐Zamorowska, Eliza; Jarosz‐Chobot, Przemysława
- Abstract
Objectives: The aim of the study was to assess the benefits of a predictive low glucose suspend (PLGS) system in real‐life in children and adolescents with type 1 diabetes of different age and age‐related clinical challenges. Methods: Real life retrospective and descriptive analysis included 44 children (26 girls) with type 1 diabetes who were introduced to PLGS system. We divided them in three age groups: I (3‐6 years old, n = 12), II (7‐10 y/o, n = 16), III (11‐19 y/o, n = 16). All children and their caregivers received unified training in self‐management during PLGS therapy. Patients' data included: age, HbA1C levels, sex. While from the CGM metric, we obtained: time of sensor use (SENSuse), time in range (TiR): in, below and over target range and average blood glycemia (AVG), insulin suspension time (INSsusp). Results: SENSuse was 93% in total, with 92%, 94%, and 87% in age groups I, II, III, respectively. In total the reduction of mean HbA1C from 7.61% to 6.88% (P <.05), while for the I, II, and III it was 7.46% to 6.72%, 6.91% to 6.41%, and 8.46 to 7.44%, respectively (P <.05). Although we observed a significant reduction of HbA1C, the time below target range was minimal. Specific findings included: group I—longest INSsusp (17%), group II—lowest glycemic variability (CV) (36%), and group III—highest AVG (169 mg/dL). There was a reverse correlation between suspend before low and age (−0.32, P <.05). In group I CV reduced TiR in target range (TiRin) (−0.82, P <.05), in group II use of complex boluses increased TiRin (0.52, P <.05). In group III higher CV increased HbA1C (0.64, P <.05) while reducing TiRin (−0.72, P <.05). Conclusions: PLGS is a suitable and safe therapeutic option for children with diabetes of all age and it is effective in addressing age‐specific challenges. PLGS improves glycemic control in children of all age, positively affecting its different parameters.
- Subjects
BLOOD sugar monitoring; GLYCOSYLATED hemoglobin; HYPOGLYCEMIA; INSULIN pumps; TYPE 1 diabetes; RESEARCH methodology; SELF-management (Psychology); RETROSPECTIVE studies; DESCRIPTIVE statistics; GLYCEMIC control; ADOLESCENCE; CHILDREN
- Publication
Pediatric Diabetes, 2020, Vol 21, Issue 2, p280
- ISSN
1399-543X
- Publication type
Article
- DOI
10.1111/pedi.12944